Figure 2 Within the SOC level, gastrointestinal system disorders in overall GLP-1 RAs were overreported compared with the background frequency (ROR 1.46, PRR 1.33, IC 0.41, EBGM 1.33), which were further attributed to liraglutide (ROR 2.39, PRR 1.84, IC 0.88, EBGM 1.33), dulaglutide (ROR 1.39, PRR 1.28, IC 0.36, EBGM 1.25), and semaglutide (ROR 3.00, PRR 2.10, IC 1.07, EBGM 2.10), while exenatide (ROR 0.57, PRR 0.63, IC 0.68, EBGM 0.63) and lixisenatide (ROR 0.51, PRR 0.57, IC 0.81, EBGM 0.57) did not show the association with gastrointestinal AEs ( Table 2 )
Still, the FDA stood its ground, giving 503A facilities until February 18 to stop production, and 503Bs until March 19but it wasnt going to enforce any of this while the lawsuit was pending
Scientific investigation focuses on the potential of this multi-pathway approach to optimize the structural integrity of the dermal barrier and minimize oxidative stress in complex tissue culture environments
Add a splash of color to your injectables and feel energized to take on the next challenge
By handling the dilution math automatically, the calculator ensures accuracy and consistency across every experiment
